{"hands_on_practices": [{"introduction": "The cornerstone of analyzing a non-inferiority trial is a clear, quantitative decision rule. This involves comparing the confidence interval for the treatment effect to a pre-specified non-inferiority margin. This first exercise provides a direct application of this fundamental principle, allowing you to practice the core calculation and decision-making process at the heart of all non-inferiority assessments [@problem_id:4591103].", "problem": "A non-inferiority trial compares a new antibiotic to an established active control, assessing the incidence rate of a specific adverse event. Let $d$ denote the incidence rate difference defined as $d = \\text{rate}_{\\text{new}} - \\text{rate}_{\\text{control}}$, measured in events per $1000$ person-years. The non-inferiority margin is $\\Delta = 1.0$, meaning the new antibiotic is considered non-inferior if the excess adverse event rate does not exceed $1.0$ event per $1000$ person-years. The point estimate of the rate difference is $\\hat{d} = 0.8$ with standard error $\\mathrm{SE}(\\hat{d}) = 0.5$. The significance level for a one-sided assessment is $\\alpha = 0.025$.\n\nUsing the Confidence Interval (CI) criterion under the large-sample normal approximation, compute the one-sided $(1-\\alpha)$ upper confidence limit for $d$. Round your answer to four significant figures. Express your final numeric answer in events per $1000$ person-years. Provide only the numeric value of this upper limit as your final answer.", "solution": "The problem is assessed to be valid. It is a well-posed, scientifically grounded question within the domain of biostatistics and epidemiology. All necessary data and definitions for a unique solution are provided, and there are no contradictions or ambiguities.\n\nThe objective is to compute the one-sided upper confidence limit for the incidence rate difference, $d$, in a non-inferiority trial. We are given the point estimate of this difference, $\\hat{d}$, its standard error, $\\mathrm{SE}(\\hat{d})$, and the one-sided significance level, $\\alpha$. The calculation will rely on the large-sample normal approximation.\n\nThe general formula for a one-sided $(1-\\alpha)$ upper confidence limit (UCL) for a parameter, based on a normally distributed estimator, is:\n$$ \\text{UCL}_{1-\\alpha} = \\text{point estimate} + z_{1-\\alpha} \\times (\\text{standard error}) $$\nIn the context of this problem, the formula is:\n$$ \\text{UCL}_{1-\\alpha}(d) = \\hat{d} + z_{1-\\alpha} \\cdot \\mathrm{SE}(\\hat{d}) $$\nwhere:\n- $\\hat{d}$ is the point estimate of the rate difference.\n- $\\mathrm{SE}(\\hat{d})$ is the standard error of the point estimate.\n- $z_{1-\\alpha}$ is the quantile of the standard normal distribution for which the cumulative probability is $1-\\alpha$. This is the critical value from the $N(0, 1)$ distribution that leaves an area of $\\alpha$ in the upper tail.\n\nThe problem provides the following values:\n- Point estimate: $\\hat{d} = 0.8$\n- Standard error: $\\mathrm{SE}(\\hat{d}) = 0.5$\n- One-sided significance level: $\\alpha = 0.025$\n\nFirst, we determine the value of the confidence level, $1-\\alpha$:\n$$ 1-\\alpha = 1 - 0.025 = 0.975 $$\nWe therefore need to find the critical value $z_{0.975}$ from the standard normal distribution. This is the value on the z-axis such that the area under the standard normal curve to its left is $0.975$. Standard statistical tables or calculators provide this value:\n$$ z_{0.975} \\approx 1.95996... $$\nFor most applications, this value is rounded to $1.96$. We will use this standard value for the calculation.\n\nNow, we substitute the given values into the formula for the upper confidence limit:\n$$ \\text{UCL}_{0.975}(d) = 0.8 + 1.96 \\cdot 0.5 $$\nPerforming the multiplication:\n$$ 1.96 \\cdot 0.5 = 0.98 $$\nAdding this to the point estimate:\n$$ \\text{UCL}_{0.975}(d) = 0.8 + 0.98 = 1.78 $$\nThe calculated one-sided upper confidence limit for the rate difference $d$ is $1.78$.\n\nThe problem requires the final answer to be rounded to four significant figures. The number $1.78$ contains three significant figures ($1$, $7$, and $8$). To express this value with four significant figures, we must add a trailing zero after the decimal point.\nThus, the value $1.78$ is written as $1.780$ to indicate a precision of four significant figures.\nThe units are events per $1000$ person-years, as specified in the problem statement for the rate difference $d$. The question asks for the numeric value only.", "answer": "$$\\boxed{1.780}$$", "id": "4591103"}, {"introduction": "A common pitfall in interpreting clinical trial results is assuming that the absence of evidence for one outcome implies evidence for another. Specifically, failing to demonstrate that a new treatment is superior does not automatically mean it is equivalent. This practice problem challenges you to move beyond simple calculation and engage in critical interpretation, dissecting the distinct hypotheses of superiority and equivalence tests and understanding why they can lead to different, and sometimes inconclusive, findings [@problem_id:4951263].", "problem": "A randomized, double-blind trial compares a new antihypertensive agent to standard therapy on the binary endpoint of treatment response. Let the risk difference be defined as $\\Delta = p_{\\text{new}} - p_{\\text{standard}}$, where larger $\\Delta$ indicates a higher response rate with the new agent. Investigators prespecified an equivalence margin $\\delta = 0.10$ (ten percentage points). At significance level $\\alpha = 0.05$, they performed a superiority analysis and also assessed equivalence using the Two One-Sided Tests (TOST) framework. The estimated difference produced a $95\\%$ confidence interval $[-0.14, 0.18]$ and a $90\\%$ confidence interval $[-0.12, 0.16]$. The superiority analysis did not achieve statistical significance at $\\alpha = 0.05$.\n\nWhich option best explains, using the formal hypothesis relationships for TOST with $\\delta$, why failure to demonstrate superiority does not imply equivalence, and correctly interprets the numeric confidence intervals?\n\nA. Superiority tests $H_{0}: \\Delta \\le 0$ versus $H_{1}: \\Delta  0$. Equivalence via TOST tests $H_{0}: \\Delta \\le -\\delta$ or $\\Delta \\ge \\delta$ versus $H_{1}: -\\delta  \\Delta  \\delta$. With $\\delta = 0.10$, the $90\\%$ confidence interval $[-0.12, 0.16]$ is not fully contained in $(-0.10, 0.10)$, so equivalence is not established even though superiority was not demonstrated.\n\nB. If the $95\\%$ confidence interval includes $0$, the treatments are equivalent, so failure to demonstrate superiority immediately implies equivalence.\n\nC. Equivalence is demonstrated whenever the $95\\%$ confidence interval lies within $(-\\delta, \\delta)$, so the absence of superiority is sufficient for equivalence if the interval is wide enough.\n\nD. Failure to show superiority implies non-inferiority, and non-inferiority is the same as equivalence; therefore not rejecting $H_{0}: \\Delta \\le 0$ means $- \\delta  \\Delta  \\delta$ holds.", "solution": "The problem is valid. The setup is scientifically and statistically sound, self-contained, and well-posed.\n\nThe analysis of a clinical trial for superiority versus equivalence involves distinct hypothesis tests, which can lead to different conclusions. Failing to demonstrate one outcome does not automatically imply the other.\n\n**1. Formal Hypothesis Statements**\n\n*   **Superiority Test**: The goal is to prove the new agent is better. The null hypothesis ($H_{0, \\text{sup}}$) is that it is not better (i.e., same or worse). For the risk difference $\\Delta = p_{\\text{new}} - p_{\\text{standard}}$, this is:\n    $$H_{0, \\text{sup}}: \\Delta \\le 0 \\quad \\text{versus} \\quad H_{1, \\text{sup}}: \\Delta > 0$$\n    The problem states this test was not significant at $\\alpha = 0.05$, meaning we fail to reject $H_{0, \\text{sup}}$.\n\n*   **Equivalence Test (TOST)**: The goal is to prove the agents are clinically similar, meaning the true difference $\\Delta$ is within a prespecified margin $(-\\delta, \\delta)$. The null hypothesis ($H_{0, \\text{eq}}$) is that they are *not* equivalent. The alternative ($H_{1, \\text{eq}}$) is that they are equivalent.\n    $$H_{0, \\text{eq}}: \\Delta \\le -\\delta \\text{ or } \\Delta \\ge \\delta \\quad \\text{versus} \\quad H_{1, \\text{eq}}: -\\delta  \\Delta  \\delta$$\n    To establish equivalence at significance level $\\alpha$, one must reject two one-sided nulls: $H_{01}: \\Delta \\le -\\delta$ and $H_{02}: \\Delta \\ge \\delta$, each at level $\\alpha$.\n\n**2. Relationship with Confidence Intervals**\n\nThe duality between hypothesis tests and confidence intervals (CIs) provides a direct evaluation method.\n\n*   To test for equivalence at significance level $\\alpha$ using TOST, one constructs a $(1-2\\alpha)$ confidence interval for $\\Delta$. Equivalence is declared if this entire interval is contained within the equivalence margin $(-\\delta, \\delta)$. For $\\alpha = 0.05$, this requires a $(1-2 \\times 0.05) = 90\\%$ confidence interval.\n\n**3. Applying the Data**\n\n*   The equivalence margin is $\\delta = 0.10$, so the equivalence region is $(-0.10, 0.10)$.\n*   The significance level is $\\alpha = 0.05$. The relevant CI for the TOST procedure is the $90\\%$ CI.\n*   The provided $90\\%$ CI for $\\Delta$ is $[-0.12, 0.16]$.\n\n**Evaluation:**\n\n*   **Superiority**: A superiority test at $\\alpha = 0.05$ corresponds to checking if the lower bound of the $90\\%$ CI is greater than $0$. Here, the lower bound is $-0.12$, which is not greater than $0$. This confirms the study failed to show superiority.\n*   **Equivalence**: We check if the $90\\%$ CI, $[-0.12, 0.16]$, is fully contained within the equivalence interval $(-0.10, 0.10)$.\n    *   The lower bound of the CI, $-0.12$, is *not* inside the interval (it is less than $-0.10$).\n    *   The upper bound of the CI, $0.16$, is *not* inside the interval (it is greater than $0.10$).\n    Since the CI is not contained within the margin, we fail to reject $H_{0, \\text{eq}}$. Equivalence is *not* established.\n\nThe study is inconclusive: it was not able to show superiority, nor was it able to show equivalence. This happens because the estimate is too imprecise (the CI is too wide).\n\n**Option-by-Option Analysis**\n\n*   **A. Superiority tests $H_{0}: \\Delta \\le 0$ versus $H_{1}: \\Delta  0$. Equivalence via TOST tests $H_{0}: \\Delta \\le -\\delta$ or $\\Delta \\ge \\delta$ versus $H_{1}: -\\delta  \\Delta  \\delta$. With $\\delta = 0.10$, the $90\\%$ confidence interval $[-0.12, 0.16]$ is not fully contained in $(-0.10, 0.10)$, so equivalence is not established even though superiority was not demonstrated.**\n    This statement is entirely correct. It accurately states the hypotheses, uses the correct $90\\%$ CI for a TOST at $\\alpha=0.05$, and correctly interprets the numerical result. It perfectly explains why the two conclusions (no superiority, no equivalence) can coexist.\n    **Verdict: Correct.**\n\n*   **B. If the $95\\%$ confidence interval includes $0$, the treatments are equivalent, so failure to demonstrate superiority immediately implies equivalence.**\n    This is incorrect. A CI including $0$ means a test of no difference is not significant; it is not a test for equivalence. Equivalence requires the CI to be narrow and contained within the margin.\n    **Verdict: Incorrect.**\n\n*   **C. Equivalence is demonstrated whenever the $95\\%$ confidence interval lies within $(-\\delta, \\delta)$, so the absence of superiority is sufficient for equivalence if the interval is wide enough.**\n    This is incorrect. It uses the wrong CI ($95\\%$ instead of $90\\%$) and falsely claims a wide interval is better for equivalence, when the opposite is true.\n    **Verdict: Incorrect.**\n\n*   **D. Failure to show superiority implies non-inferiority, and non-inferiority is the same as equivalence; therefore not rejecting $H_{0}: \\Delta \\le 0$ means $- \\delta  \\Delta  \\delta$ holds.**\n    This statement contains multiple falsehoods. Failure to show superiority does not imply non-inferiority. Non-inferiority and equivalence are distinct concepts. Failure to reject a null hypothesis does not prove the alternative hypothesis of a different test.\n    **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4951263"}, {"introduction": "Real-world clinical trials rarely proceed with the perfection of a textbook example; participant behavior, such as non-adherence to the assigned treatment, can significantly complicate the analysis. This final exercise explores the critical and often counter-intuitive impact of such non-adherence in the context of a non-inferiority trial. By comparing the Intention-to-Treat (ITT) and Per-Protocol (PP) analysis principles, you will uncover how the choice of analytical strategy can fundamentally alter the trial's conclusion, a concept of paramount importance for regulatory science [@problem_id:4591169].", "problem": "A two-arm randomized non-inferiority trial compares a new oral antibiotic to standard therapy for community-acquired pneumonia. The primary endpoint is clinical cure by day $14$. The non-inferiority margin is specified on the risk difference scale as $M=-0.10$ (new minus standard). Randomization assigns $n=500$ participants to each arm. Suppose the following hold:\n\n- Among participants who adhere to their assigned therapy (receive the assigned treatment for a full course), the cure probabilities are $p_{\\text{new,adher}}=0.80$ and $p_{\\text{std,adher}}=0.89$.\n- There is symmetric all-or-none cross-over: in each randomized arm, $20\\%$ do not adhere and instead receive the other armâ€™s therapy, while $80\\%$ adhere. Assume that non-adherence does not change the underlying efficacy of the therapy actually received.\n\nUse the intention-to-treat (ITT) principle (analyze by randomized arm) and the per-protocol (PP) principle (restrict to adherers) to address the following. Work from first principles: define the group-level cure risks under ITT as the appropriate mixture of cure risks among adherers and non-adherers, and define the PP cure risks as the adherer risks. Use large-sample Wald approximations for $95\\%$ confidence intervals for the risk difference, with standard error $\\sqrt{p_1(1-p_1)/n_1+p_0(1-p_0)/n_0}$ for arms $1$ and $0$, ignoring finite-sample and continuity corrections.\n\nWhich statement best characterizes whether ITT dilutes differences toward zero and whether this favors non-inferiority conclusions relative to PP in this scenario?\n\nA. Under symmetric $20\\%$ cross-over, the ITT estimate is diluted toward $0$ compared with the PP effect; with $n=500$ per arm and $M=-0.10$, the ITT $95\\%$ confidence interval lies entirely above $-0.10$ while the PP $95\\%$ confidence interval does not, so ITT favors concluding non-inferiority relative to PP.\n\nB. Under symmetric $20\\%$ cross-over, the ITT estimate exaggerates differences away from $0$ and is less likely than PP to conclude non-inferiority.\n\nC. With $20\\%$ non-adherence in both arms, ITT and PP produce identical risk differences and confidence intervals, so non-inferiority conclusions are unaffected.\n\nD. Because non-inferiority trials must always prefer ITT for conservatism, the ITT analysis is the only valid basis for concluding non-inferiority even if PP fails.", "solution": "The problem statement is first subject to validation.\n\n### Step 1: Extract Givens\n- **Trial Design:** Two-arm randomized non-inferiority trial.\n- **Interventions:** New oral antibiotic (new) versus standard therapy (std).\n- **Primary Endpoint:** Clinical cure by day $14$.\n- **Non-inferiority Margin:** $M = -0.10$ on the risk difference scale (new minus standard).\n- **Sample Size:** $n=500$ participants per arm.\n- **Adherer Efficacies:**\n  - Cure probability for new therapy among adherers: $p_{\\text{new,adher}} = 0.80$.\n  - Cure probability for standard therapy among adherers: $p_{\\text{std,adher}} = 0.89$.\n- **Non-adherence Pattern:**\n  - Symmetric all-or-none cross-over.\n  - In each randomized arm, $80\\%$ adhere to the assigned therapy.\n  - In each randomized arm, $20\\%$ do not adhere and receive the other arm's therapy.\n- **Assumption:** The efficacy of a therapy is independent of whether a participant was an adherer or non-adherer.\n- **Analysis Methods:**\n  - **Intention-to-Treat (ITT):** Analyze by randomized arm.\n  - **Per-Protocol (PP):** Restrict analysis to adherers.\n- **Statistical Methods:**\n  - Use large-sample Wald approximations for $95\\%$ confidence intervals (CI).\n  - The standard error (SE) for the risk difference is given by the formula $SE = \\sqrt{p_1(1-p_1)/n_1 + p_0(1-p_0)/n_0}$.\n  - The standard normal quantile for a $95\\%$ CI is $z_{0.975} \\approx 1.96$.\n  - Finite-sample and continuity corrections are to be ignored.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded:** The problem describes a standard, realistic scenario in clinical trial methodology, specifically for non-inferiority trials. The concepts of ITT, PP, non-adherence, cross-over, and the non-inferiority margin are fundamental to this field of epidemiology and biostatistics. All numerical values are plausible.\n- **Well-Posed:** The problem is well-posed. It provides all necessary data (cure probabilities, sample sizes, non-adherence rates, non-inferiority margin) and explicitly defines the analytical methods (ITT, PP) and statistical formulas (Wald CI) required to arrive at a unique, meaningful solution.\n- **Objective:** The problem is stated using clear, precise, and objective language, free of subjective or ambiguous terminology.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. The solution process may proceed.\n\n### Derivation and Analysis\n\nThe analysis requires calculating the risk difference and its $95\\%$ confidence interval under both the Per-Protocol (PP) and Intention-to-Treat (ITT) principles. A conclusion of non-inferiority is established if the lower bound of the $95\\%$ CI for the risk difference (new minus standard) is greater than the non-inferiority margin, $M = -0.10$.\n\n**1. Per-Protocol (PP) Analysis**\n\nThe PP analysis is restricted to participants who adhered to their assigned therapy.\n\n- The proportion of adherers in each arm is $80\\%$. The sample size for the PP analysis in the new arm is $n_{\\text{new,PP}} = 0.80 \\times 500 = 400$. Similarly, $n_{\\text{std,PP}} = 400$.\n- The cure probabilities for the PP populations are given as the adherer probabilities:\n  - $p_{\\text{new,PP}} = p_{\\text{new,adher}} = 0.80$\n  - $p_{\\text{std,PP}} = p_{\\text{std,adher}} = 0.89$\n- The PP risk difference is:\n  $$ \\Delta_{\\text{PP}} = p_{\\text{new,PP}} - p_{\\text{std,PP}} = 0.80 - 0.89 = -0.09 $$\n- The standard error of the PP risk difference is:\n  $$ SE(\\Delta_{\\text{PP}}) = \\sqrt{\\frac{p_{\\text{new,PP}}(1-p_{\\text{new,PP}})}{n_{\\text{new,PP}}} + \\frac{p_{\\text{std,PP}}(1-p_{\\text{std,PP}})}{n_{\\text{std,PP}}}} $$\n  $$ SE(\\Delta_{\\text{PP}}) = \\sqrt{\\frac{0.80(1-0.80)}{400} + \\frac{0.89(1-0.89)}{400}} $$\n  $$ SE(\\Delta_{\\text{PP}}) = \\sqrt{\\frac{0.16}{400} + \\frac{0.0979}{400}} = \\sqrt{\\frac{0.2579}{400}} \\approx \\sqrt{0.00064475} \\approx 0.02539 $$\n- The $95\\%$ Wald CI for the PP risk difference is $\\Delta_{\\text{PP}} \\pm 1.96 \\times SE(\\Delta_{\\text{PP}})$:\n  $$ CI_{\\text{PP}} = -0.09 \\pm 1.96 \\times 0.02539 = -0.09 \\pm 0.04976 $$\n  $$ CI_{\\text{PP}} = [-0.13976, -0.04024] $$\n- **Conclusion for PP:** The lower bound of the CI, $-0.13976$, is less than the non-inferiority margin $M = -0.10$. Therefore, the PP analysis fails to demonstrate non-inferiority.\n\n**2. Intention-to-Treat (ITT) Analysis**\n\nThe ITT analysis includes all $n=500$ participants in each arm as randomized. The observed cure probability in each arm is a mixture of outcomes from adherers and non-adherers (who cross over).\n\n- The sample sizes are $n_{\\text{new,ITT}} = 500$ and $n_{\\text{std,ITT}} = 500$.\n- **Cure probability in the arm randomized to the new therapy ($p_{\\text{new,ITT}}$):**\n  - $80\\%$ of this group adhere and receive the new therapy (cure probability $p_{\\text{new,adher}} = 0.80$).\n  - $20\\%$ of this group cross over and receive the standard therapy (cure probability $p_{\\text{std,adher}} = 0.89$).\n  - $p_{\\text{new,ITT}} = (0.80 \\times p_{\\text{new,adher}}) + (0.20 \\times p_{\\text{std,adher}}) = (0.80 \\times 0.80) + (0.20 \\times 0.89) = 0.64 + 0.178 = 0.818$.\n- **Cure probability in the arm randomized to the standard therapy ($p_{\\text{std,ITT}}$):**\n  - $80\\%$ of this group adhere and receive the standard therapy (cure probability $p_{\\text{std,adher}} = 0.89$).\n  - $20\\%$ of this group cross over and receive the new therapy (cure probability $p_{\\text{new,adher}} = 0.80$).\n  - $p_{\\text{std,ITT}} = (0.80 \\times p_{\\text{std,adher}}) + (0.20 \\times p_{\\text{new,adher}}) = (0.80 \\times 0.89) + (0.20 \\times 0.80) = 0.712 + 0.160 = 0.872$.\n- The ITT risk difference is:\n  $$ \\Delta_{\\text{ITT}} = p_{\\text{new,ITT}} - p_{\\text{std,ITT}} = 0.818 - 0.872 = -0.054 $$\n- The standard error of the ITT risk difference is:\n  $$ SE(\\Delta_{\\text{ITT}}) = \\sqrt{\\frac{p_{\\text{new,ITT}}(1-p_{\\text{new,ITT}})}{n_{\\text{new,ITT}}} + \\frac{p_{\\text{std,ITT}}(1-p_{\\text{std,ITT}})}{n_{\\text{std,ITT}}}} $$\n  $$ SE(\\Delta_{\\text{ITT}}) = \\sqrt{\\frac{0.818(1-0.818)}{500} + \\frac{0.872(1-0.872)}{500}} $$\n  $$ SE(\\Delta_{\\text{ITT}}) = \\sqrt{\\frac{0.148876}{500} + \\frac{0.111616}{500}} = \\sqrt{\\frac{0.260492}{500}} \\approx \\sqrt{0.00052098} \\approx 0.02283 $$\n- The $95\\%$ Wald CI for the ITT risk difference is $\\Delta_{\\text{ITT}} \\pm 1.96 \\times SE(\\Delta_{\\text{ITT}})$:\n  $$ CI_{\\text{ITT}} = -0.054 \\pm 1.96 \\times 0.02283 = -0.054 \\pm 0.04475 $$\n  $$ CI_{\\text{ITT}} = [-0.09875, -0.00925] $$\n- **Conclusion for ITT:** The lower bound of the CI, $-0.09875$, is greater than the non-inferiority margin $M = -0.10$. Therefore, the ITT analysis demonstrates non-inferiority.\n\n**3. Comparison and Option Evaluation**\n\n- **Dilution Effect:** The PP risk difference is $\\Delta_{\\text{PP}} = -0.09$. The ITT risk difference is $\\Delta_{\\text{ITT}} = -0.054$. Since $|\\Delta_{\\text{ITT}}|  |\\Delta_{\\text{PP}}|$, the symmetric cross-over has diluted the observed effect estimate towards the null value of $0$.\n- **Effect on Conclusion:** The PP analysis failed to show non-inferiority, while the ITT analysis succeeded. In this scenario, using the ITT principle favors the conclusion of non-inferiority compared to using the PP principle.\n\n**Option-by-Option Analysis**\n\n**A. Under symmetric $20\\%$ cross-over, the ITT estimate is diluted toward $0$ compared with the PP effect; with $n=500$ per arm and $M=-0.10$, the ITT $95\\%$ confidence interval lies entirely above $-0.10$ while the PP $95\\%$ confidence interval does not, so ITT favors concluding non-inferiority relative to PP.**\n- This statement accurately summarizes the derived results. The ITT estimate ($-0.054$) is indeed diluted toward $0$ compared to the PP estimate ($-0.09$). The ITT CI lower bound ($-0.09875$) is above $-0.10$, while the PP CI lower bound ($-0.13976$) is not. Consequently, the ITT analysis leads to a non-inferiority conclusion where the PP analysis does not.\n- **Verdict: Correct.**\n\n**B. Under symmetric $20\\%$ cross-over, the ITT estimate exaggerates differences away from $0$ and is less likely than PP to conclude non-inferiority.**\n- The ITT estimate of the difference, $\\Delta_{\\text{ITT}}=-0.054$, is smaller in magnitude than the PP estimate, $\\Delta_{\\text{PP}}=-0.09$. Thus, it represents a dilution toward $0$, not an exaggeration. In this specific case, it was more likely, not less likely, to conclude non-inferiority.\n- **Verdict: Incorrect.**\n\n**C. With $20\\%$ non-adherence in both arms, ITT and PP produce identical risk differences and confidence intervals, so non-inferiority conclusions are unaffected.**\n- The calculations clearly show that the risk differences ($\\Delta_{\\text{ITT}} = -0.054$ vs. $\\Delta_{\\text{PP}} = -0.09$) and the confidence intervals ($CI_{\\text{ITT}} \\approx [-0.099, -0.009]$ vs. $CI_{\\text{PP}} \\approx [-0.140, -0.040]$) are not identical.\n- **Verdict: Incorrect.**\n\n**D. Because non-inferiority trials must always prefer ITT for conservatism, the ITT analysis is the only valid basis for concluding non-inferiority even if PP fails.**\n- This statement contains a critical flaw in reasoning. In superiority trials, ITT is generally conservative because dilution biases the effect toward the null, making it harder to show a difference. However, in non-inferiority trials, this same dilution toward the null can be *anti-conservative*, making it easier to claim that a new, inferior treatment is non-inferior (as demonstrated in this problem). For this reason, regulatory bodies often require that non-inferiority be demonstrated in both the ITT and PP populations to ensure a robust conclusion. The premise that ITT is \"always\" preferred for \"conservatism\" in non-inferiority trials is false.\n- **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4591169"}]}